Record Q2, Standalone Outlook, and New CFO at Resideo
REZI sits 38% above its 52-week low of $18.585.
Summary
Resideo reported record Q2 2026 results, initiated standalone 2026 guidance, and appointed Shane Harrison as CFO.
Key Events · Earnings and Guidance · REZI
-
Record Q2 Revenue and Profit
Revenue of $1.98 billion, up 2% year-over-year, with net income of $97 million versus a net loss of $825 million in Q2 2025. Adjusted EBITDA rose 19% to $249 million.
-
Standalone 2026 Guidance Initiated
Following the ADI spin-off, Resideo projects standalone 2026 revenue of $2.9-$2.95 billion and adjusted EBITDA of $605-$625 million.
-
New CFO Appointed
Shane Harrison, formerly CFO of NRC Health, will become CFO effective September 1, 2026, with a $550,000 base salary and $2 million initial equity award.
-
Spin-Off Financial Impact
Resideo received a $900 million dividend from ADIG and used it to repay $900 million of Term Loan B debt, reducing total debt obligations.
Analysis · REZI · Trade & Services
Resideo delivered record Q2 results with revenue of $1.98 billion, up 2% year-over-year, and adjusted EBITDA of $249 million, up 19%. The company also initiated standalone 2026 guidance following the ADI spin-off, projecting revenue of $2.9-$2.95 billion and adjusted EBITDA of $605-$625 million. Additionally, Shane Harrison was appointed CFO effective September 1, 2026, bringing extensive public company finance experience. The results and guidance provide clarity on Resideo's post-spin-off trajectory, while the CFO appointment fills a key leadership gap.
At the time of this filing, REZI was trading at $25.71 on NYSE in the Trade & Services sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $18.59 to $31.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.